Influence of best objective response to first‐line treatment on survival outcomes in advanced urothelial carcinoma in the era of sequential therapy with enfortumab vedotin
The best response to first-line treatment predicted both overall survival from first-line initiation and outcomes following enfortumab vedotin treatment, underscoring its prognostic value in sequential therapy for patients with advanced urothelial carcinoma.
Authors
- Kenshiro Takemoto (ORCID: https://orcid.org/0000-0002-9077-4733)
- Nobuyuki Hinata (ORCID: https://orcid.org/0000-0001-7014-6812)
- Kohei Kobatake (ORCID: https://orcid.org/0000-0003-2098-3916)
- Miki Naito (ORCID: https://orcid.org/0000-0003-3485-0751)
- Yohei Sekino (ORCID: https://orcid.org/0000-0003-1525-5463)
- Akihiro Goriki
- Kensuke Nishida
- Shunsuke Miyamoto (ORCID: https://orcid.org/0000-0001-8397-115X)
- Tetsutaro Hayashi
- Keisuke Hieda (ORCID: https://orcid.org/0000-0001-5182-8666)
- Keisuke Goto (ORCID: https://orcid.org/0000-0002-3580-1401)
- Akihiro Asami
- Hiroyuki Kitano (ORCID: https://orcid.org/0000-0002-4756-2356)
- Yuki Sakamoto (ORCID: https://orcid.org/0000-0001-8353-1787)
- Hideo Iwamoto
- Kyohsuke Iwane
- Kunihiro Hashimoto
Institutions
- Hiroshima University (JP)
- Hiroshima General Hospital (JP)
- Hiroshima City Asa Citizens Hospital (JP)
- Matsuyama Red Cross Hospital (JP)
- Hiroshima University Hospital (JP)
- Higashihiroshima Medical Center (JP)
- Hiroshima Prefectural Rehabilitation Center (JP)
- Onomichi General Hospital (JP)
Publication Details
- Journal
- International Journal of Urology
- Published
- 2025-02-10
- DOI
- https://doi.org/10.1111/iju.15686
- Citations
- 7
- Primary Topic
- Bladder and Urothelial Cancer Treatments
- Type
- article
- Field-Weighted Citation Impact
- 14.04